Jacobi Capital Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $441K | Hold |
2,321
| – | – | 0.02% | 478 |
|
|
2026
Q1 | $392K | Buy |
2,321
+17
| +0.7% | +$2.91K | 0.02% | 479 |
|
|
2025
Q4 | $389K | Hold |
2,304
| – | – | 0.02% | 472 |
|
|
2025
Q3 | $333K | Sell |
2,304
-40
| -2% | -$5.46K | 0.02% | 489 |
|
|
2025
Q2 | $296K | Sell |
2,344
-2
| -0.1% | -$246 | 0.02% | 499 |
|
|
2025
Q1 | $300K | Sell |
2,346
-352
| -13% | -$47.7K | 0.02% | 481 |
|
|
2024
Q4 | $357K | Buy |
2,698
+22
| +0.8% | +$3.09K | 0.03% | 423 |
|
|
2024
Q3 | $390K | Buy |
2,676
+131
| +5% | +$19K | 0.03% | 403 |
|
|
2024
Q2 | $349K | Buy |
2,545
+15
| +0.6% | +$2K | 0.03% | 382 |
|
|
2024
Q1 | $347K | Sell |
2,530
-75
| -3% | -$10.2K | 0.03% | 364 |
|
|
2023
Q4 | $354K | Buy |
2,605
+66
| +3% | +$8.05K | 0.04% | 346 |
|
|
2023
Q3 | $310K | Buy |
2,539
+91
| +4% | +$11.6K | 0.04% | 349 |
|
|
2023
Q2 | $311K | Buy |
2,448
+95
| +4% | +$12.3K | 0.03% | 347 |
|
|
2023
Q1 | $304K | Hold |
2,353
| – | – | 0.04% | 344 |
|
|
2022
Q4 | $309K | Buy |
2,353
+66
| +3% | +$8.53K | 0.04% | 335 |
|
|
2022
Q3 | $268K | Buy |
2,287
+128
| +6% | +$15.9K | 0.04% | 345 |
|
|
2022
Q2 | $254K | Buy |
+2,159
| New | +$256K | 0.03% | 363 |
|
|
2021
Q4 | – | Sell |
-135
| Closed | -$22K | – | 813 |
|
|
2021
Q3 | $22K | Hold |
135
| – | – | ﹤0.01% | 846 |
|
|
2021
Q2 | $22K | Hold |
135
| – | – | ﹤0.01% | 815 |
|
|
2021
Q1 | $20K | Hold |
135
| – | – | ﹤0.01% | 781 |
|
|
2020
Q4 | $20K | Sell |
135
-500
| -79% | -$71.5K | ﹤0.01% | 724 |
|
|
2020
Q3 | $86K | Hold |
635
| – | – | 0.02% | 404 |
|
|
2020
Q2 | $87K | Hold |
635
| – | – | 0.02% | 380 |
|
|
2020
Q1 | $68K | Sell |
635
-657
| -51% | -$75.6K | 0.01% | 377 |
|
|
2019
Q4 | $156K | Buy |
1,292
+12
| +0.9% | +$1.34K | 0.03% | 316 |
|
|
2019
Q3 | $127K | Buy |
1,280
+1
| +0.1% | +$105 | 0.03% | 324 |
|
|
2019
Q2 | $140K | Sell |
1,279
-200
| -14% | -$21.3K | 0.03% | 310 |
|
|
2019
Q1 | $165K | Sell |
1,479
-600
| -29% | -$65.8K | 0.04% | 250 |
|
|
2018
Q4 | $200K | Sell |
2,079
-14
| -0.7% | -$1.49K | 0.05% | 220 |
|
|
2018
Q3 | $255K | Buy |
2,093
+57
| +3% | +$6.71K | 0.07% | 179 |
|
|
2018
Q2 | $224K | Sell |
2,036
-74
| -4% | -$7.91K | 0.06% | 185 |
|
|
2018
Q1 | $216K | Sell |
2,110
-12,552
| -86% | -$1.39M | 0.06% | 170 |
|
|
2017
Q4 | $1.59M | Sell |
14,662
-14,369
| -49% | -$1.54M | 0.51% | 34 |
|
|
2017
Q3 | $3.29M | Sell |
29,031
-1,461
| -5% | -$156K | 1.11% | 18 |
|
|
2017
Q2 | $3.15M | Buy |
30,492
+1,647
| +6% | +$162K | 1.22% | 18 |
|
|
2017
Q1 | $2.76M | Buy |
28,845
+12,000
| +71% | +$1.15M | 1.41% | 17 |
|
|
2016
Q4 | $1.56M | Buy |
16,845
+16,800
| +37,333% | +$1.53M | 0.95% | 23 |
|
|
2016
Q3 | $4K | Hold |
45
| – | – | ﹤0.01% | 581 |
|
|
2016
Q2 | $4K | Buy |
+45
| New | +$4.04K | ﹤0.01% | 563 |
|
Other funds holding IBB
WA
AFG
GIC
IHL
EAM
AP
FMI
Jacobi Capital Management's IBB Position: Q2 2026 in Review
Jacobi Capital Management held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 2,321 shares worth $441K. The position accounts for 0.02% of the portfolio, ranked #478.
Jacobi Capital Management first reported a position in IBB in Q2 2016 and has held it in 39 quarters since. The position peaked at $3.29M in Q3 2017. 421 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- Jacobi Capital Management held 2,321 shares of iShares Biotechnology ETF worth $441K as of Q2 2026.
- Jacobi Capital Management left its iShares Biotechnology ETF share count unchanged in Q2 2026.
- iShares Biotechnology ETF made up 0.02% of Jacobi Capital Management's portfolio in Q2 2026, its #478 holding.
- Jacobi Capital Management first reported a position in iShares Biotechnology ETF in Q2 2016 and has held it in 39 quarters since.
- Jacobi Capital Management's iShares Biotechnology ETF position peaked at $3.29M in Q3 2017.
- 421 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on Jacobi Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.